FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2086635535> ?p ?o ?g. }

• W2086635535 endingPage "1712" @default.
• W2086635535 startingPage "1706" @default.
• W2086635535 abstract "ObjectiveDialysis access failure is a major cause of morbidity, mortality, and cost in end-stage renal disease. We undertook a study to determine the influence of medication use on dialysis access failure.MethodsAfter institutional review board approval, we performed a retrospective analysis of all upper extremity hemodialysis accesses placed from 2005 to 2009 at the Washington DC Veterans Affairs Medical Center. For each access, the date of failure was recorded. For patients who died or were lost to follow-up, the date of the last documented functional patency (censoring) was recorded. The primary exposures were 12 medication classes. Patient demographics, behaviors, comorbidities, and access characteristics were used as covariates. Patency rates were calculated using Kaplan-Meier methods. Cox proportional hazard models controlling for patient characteristics and all medication classes, with procedures clustered within patients, were used to determine the influence of medication class on primary patency.ResultsTwo hundred sixty autogenous and 126 prosthetic newly placed accesses were identified. Of these, three lower extremity accesses and six accesses with unknown thrombosis date were excluded. Forty-five (18%) of the remaining 257 autogenous accesses were excluded for primary nonfunctionality (patent, but with inadequate venous dilatation for initial hemodialysis), because the primary outcome was long-term functional patency. The remaining 212 autogenous and 120 prosthetic accesses were analyzed. Primary patency rates at 1 and 2 years were 55.2% and 49.1% for autogenous accesses, and 50.2% and 29.7% for prosthetic accesses, respectively. On multivariable analysis, angiotensin receptor blockers (ARBs) were associated with reduced hazard of both autogenous (hazard ratio [HR], 0.35; 95% confidence interval [CI], 0.16-0.76; P = .008) and prosthetic (HR, 0.41; 95% CI, 0.18-0.95;P = .039) access failure. On subgroup analysis, ARBs prolonged autogenous access primary patency among patients receiving antiplatelet medication (aspirin, clopidogrel; HR, 0.16; 95% CI, 0.05-0.52;P = .002) but had no demonstrable benefit among patients not receiving antiplatelets (HR, 1.35; 95% CI, 0.34-5.31;P = .670). There were no significant drug–drug interactions in the analysis of prosthetic accesses. Weighted regression models demonstrated low multicollinearity among the model variables.ConclusionOur data suggest that therapy with an ARB plus antiplatelet agent is associated with prolonged autogenous access primary patency, and therapy with an ARB with or without antiplatelet agents is associated with prolonged prosthetic access primary patency. Randomized studies are needed to confirm the causal role of ARBs and to determine the optimal therapeutic regimen (dose, timing, and duration) to promote access patency. Dialysis access failure is a major cause of morbidity, mortality, and cost in end-stage renal disease. We undertook a study to determine the influence of medication use on dialysis access failure. After institutional review board approval, we performed a retrospective analysis of all upper extremity hemodialysis accesses placed from 2005 to 2009 at the Washington DC Veterans Affairs Medical Center. For each access, the date of failure was recorded. For patients who died or were lost to follow-up, the date of the last documented functional patency (censoring) was recorded. The primary exposures were 12 medication classes. Patient demographics, behaviors, comorbidities, and access characteristics were used as covariates. Patency rates were calculated using Kaplan-Meier methods. Cox proportional hazard models controlling for patient characteristics and all medication classes, with procedures clustered within patients, were used to determine the influence of medication class on primary patency. Two hundred sixty autogenous and 126 prosthetic newly placed accesses were identified. Of these, three lower extremity accesses and six accesses with unknown thrombosis date were excluded. Forty-five (18%) of the remaining 257 autogenous accesses were excluded for primary nonfunctionality (patent, but with inadequate venous dilatation for initial hemodialysis), because the primary outcome was long-term functional patency. The remaining 212 autogenous and 120 prosthetic accesses were analyzed. Primary patency rates at 1 and 2 years were 55.2% and 49.1% for autogenous accesses, and 50.2% and 29.7% for prosthetic accesses, respectively. On multivariable analysis, angiotensin receptor blockers (ARBs) were associated with reduced hazard of both autogenous (hazard ratio [HR], 0.35; 95% confidence interval [CI], 0.16-0.76; P = .008) and prosthetic (HR, 0.41; 95% CI, 0.18-0.95;P = .039) access failure. On subgroup analysis, ARBs prolonged autogenous access primary patency among patients receiving antiplatelet medication (aspirin, clopidogrel; HR, 0.16; 95% CI, 0.05-0.52;P = .002) but had no demonstrable benefit among patients not receiving antiplatelets (HR, 1.35; 95% CI, 0.34-5.31;P = .670). There were no significant drug–drug interactions in the analysis of prosthetic accesses. Weighted regression models demonstrated low multicollinearity among the model variables. Our data suggest that therapy with an ARB plus antiplatelet agent is associated with prolonged autogenous access primary patency, and therapy with an ARB with or without antiplatelet agents is associated with prolonged prosthetic access primary patency. Randomized studies are needed to confirm the causal role of ARBs and to determine the optimal therapeutic regimen (dose, timing, and duration) to promote access patency." @default.
• W2086635535 created "2016-06-24" @default.
• W2086635535 creator A5027788765 @default.
• W2086635535 creator A5034528167 @default.
• W2086635535 creator A5038189143 @default.
• W2086635535 creator A5049261258 @default.
• W2086635535 creator A5084640865 @default.
• W2086635535 date "2011-12-01" @default.
• W2086635535 modified "2023-10-14" @default.
• W2086635535 title "Angiotensin receptor blockers and antiplatelet agents are associated with improved primary patency after arteriovenous hemodialysis access placement" @default.
• W2086635535 cites W1496842850 @default.
• W2086635535 cites W195015772 @default.
• W2086635535 cites W1973031258 @default.
• W2086635535 cites W1991315074 @default.
• W2086635535 cites W1991848956 @default.
• W2086635535 cites W1991935454 @default.
• W2086635535 cites W2002443524 @default.
• W2086635535 cites W2004742560 @default.
• W2086635535 cites W2007231292 @default.
• W2086635535 cites W2017526128 @default.
• W2086635535 cites W2021081098 @default.
• W2086635535 cites W2033764057 @default.
• W2086635535 cites W2051319554 @default.
• W2086635535 cites W2055101436 @default.
• W2086635535 cites W2057897080 @default.
• W2086635535 cites W2063666218 @default.
• W2086635535 cites W2069651185 @default.
• W2086635535 cites W2078199018 @default.
• W2086635535 cites W2082115839 @default.
• W2086635535 cites W2123017694 @default.
• W2086635535 cites W2127738953 @default.
• W2086635535 cites W2141902433 @default.
• W2086635535 cites W2143505273 @default.
• W2086635535 cites W2162173439 @default.
• W2086635535 cites W2254934747 @default.
• W2086635535 cites W2321102683 @default.
• W2086635535 doi "https://doi.org/10.1016/j.jvs.2011.06.028" @default.
• W2086635535 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21840155" @default.
• W2086635535 hasPublicationYear "2011" @default.
• W2086635535 type Work @default.
• W2086635535 sameAs 2086635535 @default.
• W2086635535 citedByCount "14" @default.
• W2086635535 countsByYear W20866355352012 @default.
• W2086635535 countsByYear W20866355352013 @default.
• W2086635535 countsByYear W20866355352014 @default.
• W2086635535 countsByYear W20866355352016 @default.
• W2086635535 countsByYear W20866355352017 @default.
• W2086635535 countsByYear W20866355352019 @default.
• W2086635535 countsByYear W20866355352020 @default.
• W2086635535 countsByYear W20866355352022 @default.
• W2086635535 countsByYear W20866355352023 @default.
• W2086635535 crossrefType "journal-article" @default.
• W2086635535 hasAuthorship W2086635535A5027788765 @default.
• W2086635535 hasAuthorship W2086635535A5034528167 @default.
• W2086635535 hasAuthorship W2086635535A5038189143 @default.
• W2086635535 hasAuthorship W2086635535A5049261258 @default.
• W2086635535 hasAuthorship W2086635535A5084640865 @default.
• W2086635535 hasBestOaLocation W20866355351 @default.
• W2086635535 hasConcept C126322002 @default.
• W2086635535 hasConcept C141071460 @default.
• W2086635535 hasConcept C144024400 @default.
• W2086635535 hasConcept C149923435 @default.
• W2086635535 hasConcept C167135981 @default.
• W2086635535 hasConcept C194828623 @default.
• W2086635535 hasConcept C195910791 @default.
• W2086635535 hasConcept C207103383 @default.
• W2086635535 hasConcept C2775969662 @default.
• W2086635535 hasConcept C2778063415 @default.
• W2086635535 hasConcept C2779978075 @default.
• W2086635535 hasConcept C2780073493 @default.
• W2086635535 hasConcept C2780084366 @default.
• W2086635535 hasConcept C44249647 @default.
• W2086635535 hasConcept C50382708 @default.
• W2086635535 hasConcept C71924100 @default.
• W2086635535 hasConceptScore W2086635535C126322002 @default.
• W2086635535 hasConceptScore W2086635535C141071460 @default.
• W2086635535 hasConceptScore W2086635535C144024400 @default.
• W2086635535 hasConceptScore W2086635535C149923435 @default.
• W2086635535 hasConceptScore W2086635535C167135981 @default.
• W2086635535 hasConceptScore W2086635535C194828623 @default.
• W2086635535 hasConceptScore W2086635535C195910791 @default.
• W2086635535 hasConceptScore W2086635535C207103383 @default.
• W2086635535 hasConceptScore W2086635535C2775969662 @default.
• W2086635535 hasConceptScore W2086635535C2778063415 @default.
• W2086635535 hasConceptScore W2086635535C2779978075 @default.
• W2086635535 hasConceptScore W2086635535C2780073493 @default.
• W2086635535 hasConceptScore W2086635535C2780084366 @default.
• W2086635535 hasConceptScore W2086635535C44249647 @default.
• W2086635535 hasConceptScore W2086635535C50382708 @default.
• W2086635535 hasConceptScore W2086635535C71924100 @default.
• W2086635535 hasIssue "6" @default.
• W2086635535 hasLocation W20866355351 @default.
• W2086635535 hasLocation W20866355352 @default.
• W2086635535 hasOpenAccess W2086635535 @default.
• W2086635535 hasPrimaryLocation W20866355351 @default.
• W2086635535 hasRelatedWork W113810927 @default.
• W2086635535 hasRelatedWork W2013507026 @default.
• W2086635535 hasRelatedWork W2105571831 @default.

• next